去纤维钠价格多少？去哪买到？

On October 22, 2013, (Defibrotide Sodium) was approved for marketing by the European Union as the first treatment for severe hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation. On March 30, 2016, the U.S. Food and Drug Administration (FDA) approved defibrotide (defibrotide sodium) for the treatment of hepatic veno-occlusive disease (VOD) caused by hematopoietic stem cell transplantation in adults and children with renal and pulmonary dysfunction. Defibrotide (Defibrotide Sodium) is the first and only drug for the treatment of severe hepatic veno-occlusive disease. How much does Defibrotide (Defibrotide Sodium) cost? Where can I buy it?

According to Medical Companion Travel, defibrotide (sodium defibrination) has not yet been officially launched in mainland China, but it has been launched abroad. The price of defibrination (sodium defibrination) listed abroad is about 22,000. Patients can purchase medicines by going abroad in person. This method is suitable for patients with better families. You can directly go to foreign hospitals to get medicines. However, patients from ordinary families say that they do not have the energy and financial resources to go abroad, so we can choose a formal medical service company, such as Medical Companion Travel. Obtain legal drug purchasing channels through the company, and the drugs are also delivered directly to your doorstep.

In addition, the editor does not recommend that you choose personal purchasing. Not only does this method not have drug protection, but it also has greater risks.

Hepatic veno-occlusive disease (HVOD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), and the mortality rate in patients with severe HVOD can be as high as 100%. Defibrotide (sodium defibrotide) is a mixture of single-stranded oligonucleotides with anti-thrombotic and fibrinolytic effects. In recent years, multiple clinical research results have shown that defibrotide (sodium defibrination) is a safe and effective drug for preventing and treating HVOD after HSCT.

The recommended dose of defibrotide (Defibrotide Sodium) for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Administer defibrotide (sodium defibrotide) for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrination until resolution of VOD or up to a maximum of 60 days. Patients must follow medical advice and use (defibrinated sodium) under the guidance of a doctor.

Recommended related articles: Defibrinoside (Defibrotide Sodium) Injection Method